1. Is Sun Pharma Advanced Research Company Ltd a good quality company?
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Sun Pharma Advanced Research Company Ltd is a below average quality company.
2. Is Sun Pharma Advanced Research Company Ltd undervalued or overvalued?
The key valuation ratios of Sun Pharma Advanced Research Company Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Sun Pharma Advanced Research Company Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Sun Pharma Advanced Research Company Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||-21.1%||18%||-31.8%||-71.3%||-95.7%||-134.4%||-59.5%||-180.1%||-264%||-233.7%||-|
|Value Creation Index ⓘ||-2.5||0.3||-3.3||-6.3||-8.1||-11.0||-5.3||NA||NA||NA||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||91.4%||-6.8%||3.6%||12.2%||-56.8%||133.7%||-58%||229.3%||-45.7%||-|
|Adj EPS ⓘ||-1||1.1||-1.7||-3||-4.9||-9.3||-5.5||-12||-5.9||-7.6||-7.3|
|YoY Gr. Rt. %||-||NA||-252.3%||NA||NA||NA||NA||NA||NA||NA||-|
|BVPS (₹) ⓘ||4.5||5.8||4.2||1.2||6.4||3.7||11.3||-0.7||-6.4||-7.5||-8.3|
|Adj Net Profit ⓘ||-23||26.1||-39.6||-69.8||-120||-234||-144||-314||-153||-206||-238|
|Cash Flow from Ops. ⓘ||-95.3||36.9||-41.2||-44.2||-128||-183||-172||-211||-152||-208||-|
|Debt/CF from Ops. ⓘ||-0.9||0.1||-0.1||-1.3||-0||-0||-0||-0.3||-1.5||-0.4||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||NA||NA||NA||NA|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||-109.8||21||-33.2||-106.1||-126.7||-136.6||-60||-226||164.2||301||93|
|Op. Profit Mgn % ⓘ||-19||20.1||-22.5||-39||-67.7||-310||-79.1||-397.7||-53.4||-135.5||-148.3|
|Net Profit Mgn % ⓘ||-26.3||15.6||-25.4||-43.3||-66.5||-299.2||-78.9||-408.3||-60.7||-150.3||-161.2|
|Debt to Equity ⓘ||0.8||0||0||1.9||0||0||0||-3.6||-1.4||-0.4||-|
|Working Cap Days ⓘ||110||161||200||163||210||641||254||554||177||355||209|
|Cash Conv. Cycle ⓘ||-27||-63||-80||-130||-170||-113||-272||-254||-119||-60||0|
Return on Equity has increased versus last 3 years average to 93.00%
Sales growth is good in last 4 quarters at 54.38%
Sales growth has been subdued in last 3 years 0.00%
|TTM EPS (₹)||-7.3||-|
|TTM Sales (₹ Cr.)||147||-|
|BVPS (₹.) ⓘ||-8.3||-|
|Reserves (₹ Cr.) ⓘ||-301||-|
|From the Market|
|52 Week Low / High (₹)||172.45 / 348.10|
|All Time Low / High (₹)||38.44 / 593.93|
|Market Cap (₹ Cr.)||6,370|
|Equity (₹ Cr.)||32.5|
|Face Value (₹)||1|
|Industry PE ⓘ||23.2|
Sun Pharma Advanced Research Company (SPARC) is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. SPARC was formed in 2007 through a demerger from SUN PHARMA, a global leader in speciality generics. It strive to build an enduring innovation engine built on strong scientific execution, high value analytics and aggressive portfolio management. A robust mix of internal ideation and strategic partnering with academic innovators and bio-pharma entrepreneurs fuel engine with potentially high impact ideas.
The company partner with thought-leading clinicians across the world for ideas and access. Innovation through integration of partner knowledge and efficient internal execution shapes future. SPARC is a vibrant innovation community spread over three locations globally. It endeavour to develop a meritocracy which takes pride in continuous learning and re-invention. SPARC is a responsible public company committed to maintaining highest standards of ethics and transparency.
Business area of the company
The company is engaged in the pharmaceutical research and development. The company’s core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems (NDDS).